Promising efficacy with a new combination of 2 approved drugs – Lenvima plus Keytruda

Published on January 21, 2020


In this trial, 137 cancer patients with NO AVAILABLE STANDARD THERAPEUTIC OPTIONS were treated with the combination of Lenvima plus Keytruda.

Eligible patients had metastatic Renal Cell Carcinoma (RCC), Endometrial Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Melanoma, Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer.


At 24 weeks, this is the percentage of patients that were still responding to the combination and their cancer has stopped from continuous growing and/or has shrunk:

Adverse Events

The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%).


The combination of Lenvima plus Keytruda had promising efficacy among patients with selected solid tumors, with a manageable safety profile.

The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU


Do not give up on life!

Contact us 24/7 for free service matching:

Call center +44.2082.426.039


For further reading

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics